Manufactured by Novartis.
Currently (1 Nov 2000) being trialled in UK led by Newcastle.
Inhibits Bcr-Abl tyrosine kinase by binding to ATP binding site.
Bcr-Abl is the chimeric tyrosine kinase formed from the
fusion of abl on chromosome 9 to the bcr gene on chromosome 22